JW Pharmaceutical exports new Atopic dermatitis therapy technology to LEO Pharma

Published: 2018-08-29 16:29:57

Updated: 2018-08-29 16:29:57

JW Pharmaceutical(CEO Jae-Kwang Jeon & Young-Sup Shin) announced on the 24^th that they signed a license-out agreement of its innovative Atopic dermatitis therapy ‘JW1601’ with LEO Pharma(CEO Gitte Aabo) having specialized competitiveness in the dermatologic field.

LEO Pharma, the top dermatologic company established in Denmark in 1908, has developed and supplied various dermatologic treatments...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.